Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ARIpiprazole in Anorexia NErvosa (ARIANE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01082848
Recruitment Status : Unknown
Verified February 2013 by Juan A. Arnaiz, Hospital Clinic of Barcelona.
Recruitment status was:  Recruiting
First Posted : March 9, 2010
Last Update Posted : February 22, 2013
Sponsor:
Information provided by (Responsible Party):
Juan A. Arnaiz, Hospital Clinic of Barcelona

Brief Summary:
Evidence is lacking on the effects of different psychotropic drugs in the treatment of anorexia nervosa (AR). However, HVA levels seem to be elevated in this disease, therefore suggesting a role for drugs with a partial agonist profile on dopaminergic receptors. This is a pilot study assessing the effects of aripiprazole in teenagers with AR, compared with a placebo.

Condition or disease Intervention/treatment Phase
Anorexia Nervosa Drug: aripiprazole Drug: placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Aripiprazole in the Treatment of Anorexia Nervosa in Teenagers: a Pilot, Randomised, Double Blind, Placebo-controlled Clinical Trial
Study Start Date : March 2010
Estimated Primary Completion Date : March 2013
Estimated Study Completion Date : March 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: aripiprazole Drug: aripiprazole
10 mg QD during 26 weeks

Placebo Comparator: placebo Drug: placebo
QD during 26 weeks




Primary Outcome Measures :
  1. Eating Disorder Inventory-2 [ Time Frame: 6 months ]
  2. Eating attitudes test (EAT) [ Time Frame: 6 months ]
  3. Brown Assessment of Beliefs Scale (BABS) [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. BMI [ Time Frame: 6 months ]
    Body mass index

  2. BDI [ Time Frame: 6 months ]
    Beck Depression Inventory



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age between 12 and 18
  • diagnostic criteria for anorexia Nervosa (DSM-IV-TR (includes BMI below 17.5kg/m2 and above 14 kg/m2) confirmed by a Psychiatrist and validated by K-SADS-PL interview
  • severity criteria requiring Hospital admission
  • Consent given by parents and patients

Exclusion Criteria:

  • psychotic illness
  • antipsychotic therapy at inclusion
  • pregnancy and breastfeeding
  • antipsychotic drug allergy
  • prior head trauma, malignant neuroleptic syndrome or epilepsy
  • relevant comorbidities requiring therapy
  • detection of abuse drugs in urine test
  • treatment with neuroleptic, antidepressant or mood stabilizers during 2 weeks prior to randomization (4 weeks in case of fluoxetine)
  • suicidal or homicidal thoughts
  • IQ below 70

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01082848


Contacts
Layout table for location contacts
Contact: Jaime Moyá, MD 0034932275400 ext 3482 jmoya1@clinic.ub.es

Locations
Layout table for location information
Spain
Hospital Clinic Recruiting
Barcelona, Catalonia, Spain, 08036
Contact: Jaime Moyá, MD    0034932275400 ext 3482    jmoya1@clinic.ub.es   
Principal Investigator: Jaime Moyá, MD         
Sponsors and Collaborators
Juan A. Arnaiz
Layout table for additonal information
Responsible Party: Juan A. Arnaiz, Dr, Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier: NCT01082848    
Other Study ID Numbers: ARIANE
2009-010082-23 ( EudraCT Number )
First Posted: March 9, 2010    Key Record Dates
Last Update Posted: February 22, 2013
Last Verified: February 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Anorexia
Anorexia Nervosa
Signs and Symptoms, Digestive
Signs and Symptoms
Feeding and Eating Disorders
Mental Disorders
Aripiprazole
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Dopamine D2 Receptor Antagonists
Dopamine Antagonists